ArticleCancer medicine2026
Diabetes Among Finnish Pancreatic Cancer Patients: Prevalence, Time Interval Between Diabetes and Cancer Diagnosis, and Overall Survival.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionNew-onset diabetes (NOD) potentially associated with pancreatic cancer (PC) requires further investigation to assess its potential as a tool for PC screening. MATERIAL AND
methodsIn this longitudinal nationwide register study, which includes 14,712 PC patients and 18 years of follow-up time (2000-2018), we aimed to assess the prevalence of diabetes by using a large national registry. Survival was analyzed according to diabetes status and duration (long-term diabetes, i.e., DM diagnosed > 3 years prior to PC, NOD, i.e., DM diagnosed 0-3 years prior to PC, or DM diagnosed after PC diagnosis) and treatment status (curative intent vs. palliative) using multivariable Cox regression analysis.
resultsOverall, 18% of PC patients had diabetes. The median time interval between DM and PC diagnoses was 4.8 months. In the multivariable Cox regression analysis, only DM diagnosed after PC was associated with worse survival, both in the palliative intent treatment group (HR 1.12, 95% CI 1.03-1.23, p = 0.011) and in the curative intent treatment group (HR 1.44, 95% CI 1.14-1.81, p = 0.002). Among patients diagnosed with diabetes prior to PC, neither long-term nor NOD significantly affected survival.
conclusionsMost of the diabetic PC-patients have been diagnosed with DM within a close proximity of cancer diagnosis. The progression from diabetes to clinically detectable cancer seems to be rapid-less than 6 months. Given the aggressive nature of PC and the fact that NOD can be an early sign, screening may need to begin at the time of diabetes diagnosis. The fact that a DM diagnosis made after a PC diagnosis is associated with worse survival may suggest that pancreatic tumors that cause hyperglycemia are particularly aggressive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.